关键信息
-
基因名
IFNW1
- 应用
-
别名
IFNW1；Interferon omega-1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P05000
-
表达区间
1-195aa
-
氨基酸序列
MALLFPLLAA LVMTSYSPVG SLGCDLPQNH GLLSRNTLVL LHQMRRISPF LCLKDRRDFR FPQEMVKGSQ LQKAHVMSVL HEMLQQIFSL FHTERSSAAW NMTLLDQLHT GLHQQLQHLE TCLLQVVGEG ESAGAISSPA LTLRRYFQGI RVYLKEKKYS DCAWEVVRME IMKSLFLSTN MQERLRSKDR DLGSS
-
分子量
22 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
IFNW1 (Interferon lambda 1) is a cytokine that plays a critical role in the immune response, especially against viral infections. It belongs to the type III interferon family, which includes IFNL1, IFNL2, and IFNL3. Unlike other interferons, IFNW1 primarily interacts with specific receptors on epithelial and immune cells, facilitating antiviral responses and influencing inflammation. Research on IFNW1 has gained momentum due to its potential therapeutic applications in various diseases, including viral hepatitis, cancer, and autoimmune disorders. Studies have shown that IFNW1 can enhance the antiviral activity of immune cells and promote the regeneration of infected tissues. Scientists are particularly interested in the development of recombinant IFNW1 proteins to explore their efficacy as therapeutic agents. These recombinant proteins can be engineered to improve stability, potency, and delivery methods, offering promising strategies for treating diseases where immune modulation is desirable. As our understanding of the mechanisms underlying IFNW1's actions expands, the potential for developing targeted therapies based on this cytokine becomes increasingly significant, paving the way for innovative treatments in the field of immunotherapy and infectious diseases.
